Myriad Genetics: Paul Diaz
Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine.
Crown Bioscience: John Gu
Crown Bioscience has been appointed John Gu as chief operations officer. Gu joins Crown Bio from WuXi Nextcode, where he was general manager for the China business and chief digital officer. Prior to WuXi, Gu was held successive senior technology and operations roles across digital and technology companies, including Alcatel-Lucent.
Integrity Laboratories: Maria Cekanova
Integrity Laboratories has appointed Maria Cekanova CSO. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity recently received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.